Benzinga · Oct 6, 2026
Lake Street Maintains Buy on Rezolute, Raises Price Target to $12
Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $9 to $12.
RZ
NASDAQ · RZLT
Rezolute, Inc.
Healthcare · Biotechnology
$4.22
Up+$0.11 (+2.68%)
Updated Oct 29, 2026, 12:42 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 129.35M
- P/E ratio
- -1.87
- Dividend yield
- 0.00%
- 52-week range
- $2.29 – $5.64
- Volume
- 1.41M
- Avg. volume
- 1.66M
Price performance · RZLT
RZLT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
RZLT closed at $4.22 after 21 trading sessions, up 1.93% for the selected period.
- Last close
- $4.22
- Period change
- +1.93%
- Period low
- $3.58
- Period high
- $4.87
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $4.11 | $4.24 | $4.02 | $4.22 | 1.41M |
| Oct 27, 2026 | $3.80 | $4.14 | $3.7785 | $4.11 | 1.4M |
| Oct 26, 2026 | $3.87 | $3.89 | $3.73 | $3.82 | 1.54M |
| Oct 23, 2026 | $3.78 | $3.9375 | $3.70 | $3.855 | 1.2M |
| Oct 22, 2026 | $3.67 | $3.965 | $3.67 | $3.86 | 1.36M |
| Oct 21, 2026 | $3.70 | $3.785 | $3.645 | $3.70 | 930.01K |
| Oct 20, 2026 | $3.66 | $3.8399 | $3.63 | $3.70 | 1.23M |
| Oct 19, 2026 | $3.62 | $3.72 | $3.37 | $3.70 | 1.78M |
| Oct 16, 2026 | $3.90 | $3.99 | $3.56 | $3.58 | 1.4M |
| Oct 15, 2026 | $4.25 | $4.33 | $3.90 | $3.90 | 2.12M |
| Oct 14, 2026 | $4.52 | $4.70 | $4.21 | $4.23 | 1.7M |
| Oct 13, 2026 | $4.825 | $4.85 | $4.56 | $4.61 | 1.51M |
| Oct 12, 2026 | $4.86 | $4.91 | $4.72 | $4.87 | 1.01M |
| Oct 9, 2026 | $4.60 | $4.91 | $4.55 | $4.87 | 1.87M |
| Oct 8, 2026 | $4.33 | $4.685 | $4.32 | $4.64 | 2.2M |
| Oct 7, 2026 | $4.29 | $4.56 | $4.23 | $4.38 | 1.69M |
| Oct 6, 2026 | $4.64 | $4.64 | $4.1501 | $4.32 | 2.19M |
| Oct 5, 2026 | $4.05 | $4.535 | $3.8201 | $4.33 | 4.2M |
| Oct 2, 2026 | $4.13 | $4.20 | $3.965 | $4.01 | 1.65M |
| Oct 1, 2026 | $4.14 | $4.175 | $4.04 | $4.07 | 981.72K |
| Sep 30, 2026 | $4.19 | $4.345 | $4.135 | $4.14 | 1.7M |
Latest RZLT news
The latest Smart Investors Daily articles mentioning RZLT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RZLT research
Overview
Company profile and research snapshot.
Company profile
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Lake Street | Buy | — |
| Oct 6, 2026 | Citizens | Market Outperform | — |
| Oct 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Sep 30, 2026 | Lake Street | Buy | — |
| Sep 29, 2026 | Craig-Hallum | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 6, 2026
Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15
Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and raises the price target from $11 to $15.
Benzinga · Oct 6, 2026
Cantor Fitzgerald Upgrades Rezolute to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgrades Rezolute (NASDAQ:RZLT) from Neutral to Overweight.
Yahoo · Oct 5, 2026
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
The U.S. Food and Drug Administration recommended that the company request a Type B pre-BLA meeting for Ersodetug in congenital hyperinsulinism
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
